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Abstract
Background: Ideally, the allocation of research funding for each specific type of cancer should be proportional to
its societal burden. This burden can be estimated with the metric ‘years of life lost’ (YLL), which combines overall
mortality and age at death.
Methods: Using United Kingdom data from 2010, we compared research funding from the National Cancer
Research Institute to this YLL burden metric for 26 types of cancers in order to identify the discrepancies between
cancer research funding allocation and societal burden. We also compared these values to United States data from
2010 and United Kingdom data published in 2005.
Results: Our study revealed a number of discrepancies between cancer research funding and burden. Some
cancers are funded at levels far higher than their relative burden suggests (testicular, leukaemia, Hodgkin’s lymphoma,
breast, cervical, ovarian, prostate) while other cancers appear underfunded (gallbladder, lung, nasopharyngeal, intestine,
stomach, pancreatic, thyroid, oesophageal, liver, kidney, bladder, and brain/central nervous system). United Kingdom
funding patterns over the past decade have generally moved to increase funding to previously underfunded cancers
with one notable exception showing a converse trend (breast cancer). The broad relationship between United
Kingdom and United States funding patterns is similar with a few exceptions (e.g. leukaemia, Hodgkin’s lymphoma,
prostate, testicular cancer).
Conclusions: There are discrepancies between cancer research funding allocation and societal burden in the United
Kingdom. These discrepancies are broadly similar in both the United Kingdom and the United States and, while they
appear to be improving, this is not consistent across all types of cancer.
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Background
Cancer is estimated to kill over 8.2 million people annu-
ally, including an estimated 617,229 people in the United
States and 157,849 in the United Kingdom in 2012 [1].
In order to address this peril, governments fund grants
and institutions specifically devoted to cancer treatment
research. Since financial resources are limited, it is in the
best interest of government agencies to ensure this
money is spent effectively and efficiently by devoting the
resources to cases in which the greatest benefit is likely
to be realized. This realization prompted the United
States National Institutes of Health (NIH) to recom-
mend that research effort be compared to societal bur-
den when making funding decisions [2]. Nevertheless,
studies explicitly comparing cancer research funding to
societal burden are limited in number [3–12] and often
group all types of cancer together or include other dis-
eases with different etiologies which obscure compari-
sons – we restrict our analyses to comparisons of
different types of cancer to facilitate these.* Correspondence: ashley.carter@aya.yale.edu
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Previous reports indicate that the cancer research
funding levels for different cancer types are inappropri-
ately aligned with societal burden metrics in both the
United Kingdom [3] and the United States [10]. Many
specific types of cancer appear either over- or under-
funded according to various metrics examined. Since
one of the goals of a well-designed national cancer re-
search program is to efficiently allocate resources, mis-
matches between research funding and societal burden
should be minimised. This requires two steps, (1) choos-
ing an appropriate burden metric or metrics with which
to rate each cancer and (2) shifting research funding to-
ward a distribution that exhibits equal expenditure with
respect to the burden metric or metrics identified.
The first burden metric typically considered is overall
mortality. The total number of deaths from each cancer
is the easiest epidemiological data to record and inter-
pret, but this presents an incomplete picture of the over-
all burden. For example, one may argue that the death
of a child and the death of person aged 95 years, caused
by the same particular cancer, carry different burdens.
Most people would agree that the death of the child is
the more regrettable situation and represents a larger
loss. Health care analyses therefore often adjust the soci-
etal burden of each death by taking into account the age
at which a person is killed by the cancer.
The total ‘years of life lost’ (YLL) is a simple metric
that takes into account the age at death when consider-
ing the degree of burden [3]. YLL is the number of years
longer the patient is expected to have lived in the ab-
sence of that cause of mortality. YLL is based on the
remaining life expectancy which changes as an individ-
ual ages due to sex and age group considerations. For
example, the death of a 95 year old would result in ap-
proximately 3 years lost (since such a person lives 3 add-
itional years on average) whereas the death of a 50 year
old would result in approximately 32 years lost (since
such a person lives, on average, 32 additional years). The
YLL is the total number of years lost calculated for all
individuals of all ages and is therefore a more complete
measurement of the cost or burden arising from deaths
than total mortality. YLL values have been used in previ-
ous studies of societal burden from disease (e.g. [3, 10]).
Three related statistics can be useful for considering
the burdens caused by these premature deaths. The
‘average years of life lost’ (AYLL) gives a value that rep-
resents the average severity of each individual death
using the YLL concept, but does not include information
regarding the number of cases. AYLL is calculated by
dividing the overall YLL value by the total mortality
value (equivalent to calculating an average of the
remaining life expectancy values weighted by the num-
ber of deaths in each age group). The ‘years of life lost
per incidence’ [10] divides the total YLL by the number
of incidences, which serves to reduce the value for can-
cers that may kill people when they are very young (and
therefore have very high AYLL values), but for which we
already have very high treatment efficacies (e.g. testicular
cancer). The ‘disability adjusted life-years’ (DALY) metric
sums the YLL and discounts the remaining years experi-
enced by survivors by estimating the reduction in the
quality of any remaining years of life due to disabilities
caused by the disease. The DALY is widely used, but
presents problems in comparative studies due to the sub-
jective nature of assigning quantitative values to the qual-
ity of life discounts [13, 14]. While we believe these three
metrics can also be used to provide insight into the bur-
den imposed by cancer, we will focus mainly on the YLL
in our analyses because this measures an unambiguous
overall societal burden and is free of subjective decisions
regarding disabilities and quality of life.
We analyzed burden metrics for 26 different types of
cancer in the United Kingdom and compared the values
to the funding levels provided by the National Cancer
Research Institute (NCRI) with the goal of identifying
mismatches between research funding and societal bur-
den, hereafter referred to as discrepancies. Such discrep-
ancies can then be considered on a case-by-case basis to
better understand the state of cancer research efficiency.
To place this information in a broader context we com-
pared current discrepancies in the United Kingdom to
those previously identified [3] to determine whether
funding allocation has improved with respect to equit-
ability and we compared the United Kingdom discrepan-
cies to those recently reported for the United States [10].
Methods
Mortality, YLL, and AYLL data was obtained in the fol-
lowing manner. We obtained mortality values for 2010
[15] and life expectancy values for 2011 for each 5-year
age group (i.e. 0–4, 5–9, …, 75–79, 80–85, 85+ years)
for each type of cancer for individuals living in the
United Kingdom from WHO data [16], with the excep-
tion of separate life expectancy values for ages 0–1 and
1–4, in which case the latter was used. Each YLL value
was calculated by multiplying the mortality values by the
remaining life expectancy values for each age category
and summing across all of them. Separate male and fe-
male mortality and life expectancy tables were used to
calculate sex-specific YLL values and were combined for
an overall YLL.
Funding values were obtained in the following manner.
United Kingdom research funding values for each type
of cancer were obtained from the Cancer Research
Database published by the NCRI [17]. This is the
major governmental source of cancer research funding
in the United Kingdom, analogous to the NIH in the
United States. Although this data does not represent
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all cancer research funding in the United Kingdom, it
does provide data comparable to NIH funding analyses in
the United States [10] and previous NCRI-based studies
[3]. The NCRI divides research into ‘all-sites’ and ‘non-all-
sites’ categories. We omitted the values for ‘all-sites’ and
focused on the specific categories or types of cancer. All
calculations only include the funding values for these spe-
cific cancer types.
The listed categories for cancer type are not identical
in the WHO and NCRI sources described above. Based
on the most recent International Statistical Classification
of Diseases and Related Health Problems (ICD-10) from
the WHO, some NCRI funding categories were com-
bined in order to match the WHO mortality categories.
The adjustments made were (1) Oral Cavity, Lip and
Pharynx combined and assigned to “C00-14, not C11”,
(2) Anal, Rectal and Colon combined and assigned to
“C18-21”, and (3) Brain and Central Nervous System
combined and assigned to “C70-72”. This resulted in 26
different types of cancer. We neglected all other values
for cancer mortality and funding and performed all ana-
lyses on these values, omitting very rare cancers and
funding not specifically targeted to one of the 26 cat-
egories. The 26 categories account for the vast majority
of cancer cases and over 91.49% of the NCRI funding
dedicated to specific types of cancer.
Due to its high burden and relatively low funding
levels, lung cancer represents an outlier in many statis-
tical considerations. Lung cancer causes over twice as
many deaths as the next most lethal cancer category
(anal/rectal/colon accounting for 12% of deaths) despite
receiving less funding than four other cancer types
(anal/rectal/colon, breast, prostate, and leukaemia) and
roughly the same funding as ovarian cancer (which kills
less than an eighth as many individuals). Specifically,
lung cancer accounts for 26% of cancer deaths while
receiving only 6% of cancer research funding; this
tends to obscure other relationships between funding
and societal burden if it is included in analyses. Fur-
thermore, since the main cause of lung cancer is well
known (i.e. smoking) and because most individuals
are not diagnosed until later in progression, relative
to other types of cancer, the types of lung cancer
studies funded (according to the Common Scientific
Outline research classification system [18]) focus more on
prevention (e.g. excise tax on tobacco, adopting
smoke-free laws and policies, etc.) than medical treat-
ment [19]. Due to the extreme nature of mortality
and YLL values for lung cancer and the different
manner with which research for treatments for this
cancer is prioritized, separate analyses with and with-
out lung cancer values were performed. Both sets of
results are available through a combination of the re-
sults presented in the main text which omit lung
cancer and those which include lung cancer made
available as Additional file 1.
Results
Table 1 presents the mortality, YLL, funding, and AYLL
data for the 26 cancer types for which data was available
from the NCRI and WHO sources. The mortality and
funding values are directly reported and the YLL and
AYLL values were calculated as described above. The
table also provides the abbreviations that are used in
Table 2 and the figures.
Table 2 presents the proportional values for the mortal-
ity, YLL and NCRI research funding for each cancer type
and some calculated ratios. The ratio of YLL to mortality
indicates those cancers that tend to kill younger victims.
The last two columns present the ratio of NCRI research
funding to the YLL values with and without the inclusion
of lung cancer values and the table is ordered by these.
Larger ratios in the rightmost three columns indicate can-
cer types overfunded relative to the overall funding levels
and values below unity reflect cancers that are under-
funded relative to their societal burden. The top six and
bottom eight cancer types are the same when ordered by
funding relative to either mortality or YLL while other
cancers shift within the middle region. These ratios indi-
cate research effort to societal burden discrepancies, but
they do not indicate overall societal burden; for example,
testicular cancer is by far the most overfunded type of
cancer according to both criteria, but this arises from a
very low number of testicular cancer mortalities.
The effect of including or omitting lung cancer is clear
from comparing the last two columns of Table 2. As de-
scribed in the Methods section, we believe that omitting
lung cancer shows a clearer picture of the overall fund-
ing and prioritization patterns. The figures are therefore
based on values omitting lung cancer data (i.e. using
values from the last column in Table 2), but these same
figures with lung cancer values included are available as
Additional file 2 and reference to them will occasionally
be made in the discussion.
Figures 1 and 2 compare the values obtained in this
study to those reported in 2005 for the United Kingdom
which were based on demographic data from 1994 and
funding data from 2002 [3]; we will hereafter consider
them to represent values indicative of the year 2002,
which allows comparisons approximately corresponding
to the changes over the past decade.
Figure 1 compares the research funding to YLL ratios
for the current and 2002 United Kingdom data [3].
There is a significant relationship between these values
(R2 = 0.904 with P = 1.6 × 10−7, ANOVA F test) suggest-
ing that funding discrepancies are persistent rather than
arising due to random fluctuations in funding cycles.
There are still many overfunded and underfunded
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cancers and leukaemia presents an extreme case in
which a very high degree of overfunding is apparent in
both time periods (R2 = 0.638 with P = 3.5 × 10−4,
ANOVA F test when omitting leukaemia). The figure in-
dicates that these discrepancies are generally being re-
duced, as indicated by cancer types which are above the
diagonal line for previously underfunded cancers and
below the diagonal line for previously overfunded can-
cers. A majority of the cancer types that were under-
funded in 2002 received increased funding (8 of 9) and a
majority of cancer types that were overfunded in 2002
received reduced funding (5 of 7). Lung cancer was pre-
viously underfunded and continues to be so, but to a
slightly lesser degree (Additional file 3: Figure S1).
Figure 2 compares the changes in research funding
and changes in YLL for the United Kingdom since
2002 [3], expressed in relative terms. An increase in
the relative YLL for a specific cancer type does not
necessarily mean an increase in absolute YLL; instead,
the relative severity is increasing, most likely due to
better improvements for other types of cancer. Over-
all, there is an extremely weak and non-significant re-
lationship between types of cancer that have increases
in relative YLL and those with increases in funding
(R2 = 0.016 with P = 0.645, ANOVA F test). However,
this lack of a relationship is driven by breast cancer
and an analysis omitting breast cancer results in a
stronger and statistically significant relationship (R2 =
0.321 with P = 0.028, ANOVA F test). Overall, this
figure indicates that, with the exception of breast can-
cer, funding is shifting toward cancers that lag behind
in terms of effective treatments.
Table 1 Data used in analyses. Presents the raw and calculated data used in our analyses. This table presents the ICD-10 codes,
cancer type name, abbreviation used throughout this paper, mortality, YLL, funding and AYLL data from the NCRI and WHO sources
for the 26 cancers examined in our study. The mortality and funding values are directly from the sources described; the YLL and
AYLL values were calculated as described in the text.
ICD - 10 Full Cancer Name Abbreviation Mortality YLL Funding (in £) AYLL
C00-14, not C11 Oral Cavity, Lip, & Pharyngeal Oral 2200 41,862 3,838,687 19.03
C11 Nasopharyngeal Naso 129 2,774 61,982 21.50
C15 Esophageal Eso 7616 119,251 5,431,750 15.66
C16 Stomach Stom 4967 71,851 2,487,957 14.47
C17 Intestine Int 422 6,893 210,583 16.34
C18-21 Anal, Rectal, & Colon An/Rec/Col 16046 236,029 22,668,843 14.71
C22 Liver Liver 3805 62,002 2,839,325 16.29
C23-24 Gallbladder Gall 725 10,372 94,656 14.31
C25 Pancreatic Panc 7917 124,069 4,368,188 15.67
C32 Laryngeal Larynx 761 12,618 1,469,229 16.58
C33-34 Lung* Lung 34926 548,930 11,847,782 15.72
C43 Melanoma Mela 2204 42,840 4,933,515 19.44
C50 Breast Breast 11575 219,254 42,027,686 18.94
C53 Cervix Uteri (Cervical) Cerv 940 24,862 4,287,905 26.45
C54 Corpus Uteri (Endometrial) Uter 1452 23,874 2,600,732 16.44
C56 Ovarian Ovary 4183 76,148 12,169,672 18.20
C61 Prostate Pros 10729 114,805 16,629,771 10.70
C62 Testicular Test 75 2,733 1,811,845 36.43
C64 Kidney Kid 3728 60,669 3,433,812 16.27
C67 Bladder Blad 4914 59,490 3,524,027 12.11
C70-72 Brain & Central Nervous System Br/CNS 3838 87,015 5,669,837 22.67
C73 Thyroid Thyr 346 5,347 228,627 15.45
C81 Hodgkin’s Disease H Lym 324 7,941 2,182,898 24.51
C82-85, C96 Non-Hodgkin’s Lymphoma NHL 4459 69,975 8,238,159 15.69
C88 + C99 (Multiple) Myeloma Myel 2762 39,257 4,568,972 14.21
C91-95 Leukemia Leuk 4492 71,337 32,545,100 15.88
Total: 135535 2,142,198 £ 200,171,540
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Figure 3 compares YLL values for the United Kingdom
and United States [10]. There is a clear and significant
relationship between the YLL values in the two countries
(R2 = 0.882 with P = 8.7 × 10−10, ANOVA F test) as
expected for two countries with so many cultural similar-
ities. Oesophageal cancer presents the largest deviation
from the pattern with a 1.89:1 ratio of relative YLL values.
Figure 4 compares the research funding to YLL ratios
for the United Kingdom and United States data [10].
There is a weak and almost significant relationship be-
tween these values (R2 = 0.165 with P = 0.0754, ANOVA
F test) suggesting similar research discrepancies in the
two countries. Testicular cancer and leukaemia repre-
sent outliers in which they are overfunded in both coun-
tries, although to a much higher degree in the United
Kingdom; omitting these from the analysis results in a
significant relationship between the discrepancy values
(R2 = 0.285 with P = 0.0225, ANOVA F test). The pattern
is quite scattered and a number of cancers exhibit very
different discrepancies (i.e. brain/central nervous system,
kidney, leukaemia, oral, uterine, prostate, Hodgkin’s
lymphoma, testicular) although some of this arises due
to statistical variation in cancer types for which absolute
burden or funding is low (e.g. Hodgkin’s lymphoma, tes-
ticular). Five cancer types (bladder, oesophageal, liver,
pancreatic, stomach) appear considerably underfunded
in both countries as is lung cancer (Additional file 4:
Figure S4).
Discussion
Our results indicate several discrepancies between the
relative levels of funding from the NCRI and societal
Table 2 Burden and funding proportions. Presents several proportional burdens and research funding values and their ratios. For
each cancer type, this table presents the proportions of overall mortalities, YLL and funding (2nd, 3rd, and 5th columns, respectively)
dedicated to research. The ratio of proportional YLL to proportional mortality (4th column) indicates which cancers tend to kill
younger victims. The ratio of proportional funding to proportional mortality and YLL (6th and 7th columns, respectively) indicates
which cancers appear to be overfunded (values larger than 1.0) or underfunded (values smaller than 1.0) including data for lung
cancer. The rightmost column (8th column) recalculates the funding to YLL ratio after omitting lung cancer.
Cancer Site %Mortality %YLL %YLL/%Mortality %Funding %Funding/%Mortality %Funding/%YLL
Test .06 .13 2.31 .91 16.36 7.10
Leuk 3.31 3.33 1.00 16.26 4.91 4.88
H Lym .24 .37 1.55 1.09 4.56 2.94
Breast 8.54 10.24 1.20 21.00 2.46 2.05
Cerv .69 1.16 1.67 2.14 3.09 1.85
Ovary 3.09 3.55 1.15 6.08 1.97 1.71
Pros 7.92 5.36 .68 8.31 1.05 1.55
NHL 3.29 3.27 .99 4.12 1.25 1.26
Larynx .56 .59 1.05 .73 1.31 1.25
Myel 2.04 1.83 .90 2.28 1.12 1.25
Mela 1.63 2.00 1.23 2.46 1.52 1.23
Uter 1.07 1.11 1.04 1.30 1.21 1.17
An/Rec/Col 11.84 11.02 .93 11.32 .96 1.03
Oral 1.62 1.95 1.20 1.92 1.18 .98
Br/CNS 2.83 4.06 1.43 2.83 1.00 .70
Blad 3.63 2.78 .77 1.76 .49 .63
Kid 2.75 2.83 1.03 1.72 .62 .61
Eso 5.62 5.57 .99 2.71 .48 .49
Liver 2.81 2.89 1.03 1.42 .51 .49
Thyr .26 .25 .98 .11 .45 .46
Panc 5.84 5.79 .99 2.18 .37 .38
Stom 3.66 3.35 .92 1.24 .34 .37
Int .31 .32 1.03 .11 .34 .33
Naso .10 .13 1.36 .03 .33 .24
Lung 25.77 25.62 .99 5.92 .23 .23
Gall .53 .48 .91 .05 .09 .10
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burden for the United Kingdom. Table 2 shows that
some cancers are funded at levels higher than their rela-
tive burden suggests (testicular, leukaemia, Hodgkin’s
lymphoma, breast, cervical, ovarian, prostate), while
other cancers appear underfunded (gallbladder, nasopha-
ryngeal, lung, intestine, stomach, pancreatic, thyroid,
oesophageal, liver, kidney, bladder, and brain/central ner-
vous system).
Comparisons with older United Kingdom data [3] and
recent United States data [10] also reveal interesting pat-
terns. Changes in funding in the United Kingdom over
the past decade have reduced, but not eliminated, these
discrepancies (Figure 1). Funding also appears to have
been appropriately moving toward cancer types that lag
behind others in terms of recent improvements that
have led to lower mortality rates (Figure 2) with the ex-
ception of funding for breast cancer, which is a notable
counter example. The relative severities of each type of
cancer are quite similar in the United Kingdom and
United States (Figure 3) and the pattern of funding levels
relative to YLL burden is broadly similar in both coun-
tries (Figure 4), although there are cancers that appear
differently prioritized in terms of this ratio (e.g. brain/
central nervous system, kidney, leukaemia, oral, uterine,
prostate, Hodgkin’s lymphoma, testicular). In both the
United Kingdom and the United States, bladder,
oesophageal, liver, lung, pancreatic, and stomach cancers
are considerably underfunded relative to their societal
burden as measured by both mortality and YLL.
One possible cause of differences in cancer mortalities
and funding discrepancies between the United Kingdom
and United States arises from the fact that the United
Kingdom practices comprehensive nationalized medicine
which can have several effects. First, the United King-
dom has a larger focus on regular check-ups and pre-
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Figure 1 Funding versus years of life lost (YLL) over time in the United Kingdom. Presents the research funding to YLL ratios for the United
Kingdom data in Table 2 on the Y-axis compared to 2002 data [3] on the X-axis. The dashed vertical and horizontal lines indicate points at which
proportional funding is equal to proportional YLL. The dotted diagonal line indicates identical discrepancies during both time periods. Italicized
labels are used to describe six zones within the figure that represent different combinations of patterns of discrepancy. Combinations of symbol
shape and colour/shading indicate cancer types with similar types of funding discrepancies. Cancer types which are above the diagonal line to
the left of the vertical dashed line indicate those that were previously underfunded receiving increased funding and cancer types below the
diagonal line to the right of the vertical dashed line indicate those that were previously overfunded receiving reduced funding. Not all 26 cancer
types are represented due to less comprehensive data for the older United Kingdom data set.
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diagnosing cancers at earlier, more treatable, stages. This
would decrease the YLL values preferentially for cancer
types that respond to early treatment. Second, without a
nationalized healthcare system, the United States likely
collects less complete medical data for its citizens and
we therefore expect more statistical noise in the United
States YLL values, especially for rare cancers.
Consideration of AYLL values (Table 1) has been used
as an alternative method to measure societal burden [3],
but we find this method flawed. Although AYLL places
more weight on younger people’s deaths, it ignores the
total number of cases. For example, testicular cancer has
an extremely high AYLL of 36.43 years, but less than 1%
of the total adjusted funding, which may make it appear
to be greatly underfunded, but testicular cancer has the
lowest mortality rate within our data set of 26 cancer
types with a total of only 75 deaths in 2010 and is, in
fact, overfunded when using overall YLL. Another
example is cervical cancer, which appears overfunded
(2.14% of funding, 1.16% of YLL) which may have
arisen from its unusually high AYLL value (26.45, sec-
ond highest value in our data set) despite the pres-
ence of an effective preventive mechanism (i.e. the
Human Papillomavirus vaccine and yearly pap smear
screenings) [20]. For reasons like these, our recom-
mendations focus on YLL instead of either total mor-
tality or AYLL because of the potentially misleading
nature of those metrics.
However, there are caveats to remain aware of when
matching research funding and effort directly to YLL. As
stated in the Materials and Methods section, it is argu-
able that for some cancer types (e.g. lung and cervical),
available funding could be better spent on prevention ra-
ther than treatment. This is because the risk of develop-
ing these cancers arises primarily from behavioural
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Figure 2 Funding and years of life lost (YLL) changes over time in the United Kingdom. Presents a comparison of the percentage differences in
research funding (Y-axis) and YLL (X-axis) for the United Kingdom between this study and the values reported for 2002 [3]. Data points to the
right of the vertical axis indicate cancers increasing in relative societal burden (and vice versa) while data points above the horizontal axis
represent cancers receiving increased funding (and vice versa). Combinations of symbol shape and colour/shading indicate cancer types with
concordant or discordant changes in funding and YLL. These values are relative YLL and funding so any increases in the relative YLL for a specific
cancer type would not mean increases in absolute YLL, rather that the relative severity is increasing, most likely due to better improvements for
other types of cancer. Not all 26 cancer types are represented due to less comprehensive data for the older United Kingdom data set.
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and cervical cancers, respectively) [21–23] and the
right prevention campaign could decrease burden dra-
matically without the need to develop more effective
treatments. Because our study focused primarily on
research funding provided by the government and did
not include the research efforts held by private and
commercial entities, our analysis is a partial view of
the overall research funding context. We expect that
funding discrepancies may be much higher in private
funding than in the governmental data; rare cancers
may be completely neglected by commercial entities
due to the very small potential for profit that may be
realized by developing a treatment with such a small
market. The use of societal burden as the sole metric
also lacks consideration of the complexity of perform-
ing research. Factors, such as private sector efforts,
positive feedback cycles and negative synergistic ef-
fects, can result in different conclusions regarding the
desired relationship between a simple burden metric
like YLL and research effort [10]. These other factors
are very difficult to quantify, however, and concrete
information on their effects and importance is currently
lacking. Despite these issues, organizations such as the
NCRI and NIH recommend using a funding approach
based on health metrics such as the YLL [2, 3, 10].
Our recommendations are based on the ideal of a lin-
ear relationship between societal burden (mortality or
YLL) and effort (research funding). The fit between these
burdens and effort was also explored using a variety of
other types of relationships (e.g. exponential, logarith-
mic, polynomial, etc.); only an exponential curve yielded
a better fit and the improvements were extremely minor.
The linear best-fit lines show that current funding more
closely matches a relationship between funding and YLL
than funding and mortality (R2 = 0.55 and R2 = 0.47,
respectively, if we exclude lung cancer and R2 = 0.11 and
R2 = 0.07, respectively, if lung cancer is included) al-
though the fit with YLL is only marginally better than
the fit with raw mortality.
Certain types of cancers exhibit unusual funding and
YLL relationships and therefore warrant additional dis-
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Figure 3 Years of life lost (YLL) values in the United Kingdom versus the United States. Presents the YLL burden values for the United Kingdom
on the Y-axis compared to a recent report of the same cancer types for the United States [10]. Both data analysis are based on 2010 values. The
dotted diagonal line indicates equal proportional YLL values in the two countries and residuals from this line indicate types of cancer for which
the societal burdens differ. Not all 26 cancer types are represented due to less comprehensive data for the United States data set.
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overfunded, which we feel may be due to a high level of
public awareness for this specific cancer type. Some
other cancers suffer from very low public awareness
which may account for underfunding; for example,
nasopharyngeal, intestine, gallbladder, and thyroid can-
cers, which together account for 1.2% of all YLL, only
receive 0.3% of the total research funding.
Some cancers may also be underfunded due to a social
stigma, in which it is not socially normal or appropriate
to talk openly about them and raise awareness or con-
sider burden. The very private and personal parts of the
body associated with bladder and anal/rectal/colon can-
cers may account for the relatively low level of funding
for these cancers and why there do not appear to be as
many charitable organizations addressing these types of
cancers as there are for breast cancer for example.
Figure 1 shows several cases in which funding levels
have gone from overfunded or underfunded to much
more equitably funded (melanoma and non-Hodgkin
lymphoma for the former and myeloma and uterine can-
cer for the latter). These changes may have been due to
decision makers following previous recommendations to
move resources from overfunded to underfunded can-
cers (Figure 2).
Counter-examples to this process appear in cancer
types with strong psychological and identity compo-
nents. The main exception to the improvement in allo-
cation to burden ratios appears to be breast cancer, for
which large decreases in proportional YLL over the past
decade are paired with increases in proportional re-
search funding. The disproportionately high levels of
funding for breast cancer may arise from the same emo-
tional and awareness factors that have led to the numer-
ous charitable organizations devoted to this cancer. This
more highly perceived burden may arise from the strong
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Figure 4 Funding versus years of life lost (YLL) in the United Kingdom versus the United States. Presents the research funding to YLL ratios for
the United Kingdom data in Table 3 on the Y-axis compared to a recent report of the same cancer types for the United States [10] on the X-axis.
Both data analyses are based on 2010 values. The dashed vertical and horizontal lines indicate points at which proportional funding is equal to
proportional YLL. The dotted diagonal line indicates identical discrepancies in both countries. Italicized labels are used to describe six zones within
the figure that represent different combinations of funding discrepancies. There is a generally similar pattern of ratios although testicular cancer
and leukaemia represent outliers in which they are overfunded in both countries, but to a much higher degree in the United Kingdom than in
the United States.
Carter et al. Health Research Policy and Systems  (2015) 13:62 Page 9 of 11
an embodiment of their feminine gender which adds a
societal burden not captured by mortality or YLL. Add-
itionally, since breast cancer has more widely used and
visible tests than other cancers for early tumour detec-
tion (e.g. self-exams, mammograms, etc.), awareness is
raised each time a woman performs these tests. Similar
psychological processes, when played out in men, may
account for the relatively high rates of funding for pros-
tate and testicular cancers.
Psychological and emotional factors can also be re-
sponsible for the underfunding of some cancers. It ap-
pears that lung cancer receives low level of research
funding due to a blame-the-victim-attitude, in which the
personal choice to engage in smoking is seen as the dir-
ect and exclusive cause of lung cancer [24]. Oral and
liver cancers, being linked to tobacco and alcohol use,
are also prone to this bias. The public may view the best
solution to the burden imposed by these cancers as aris-
ing not from improved medical research, but from social
and behavioural changes. This attitude seems inconsist-
ent with funding for cervical cancer, however, which is
overfunded based on relative YLL yet often arises due to
behavioural choices (e.g. sexual activity). Melanoma is
also similar in that it is highly preventable by managing
unprotected sun exposure. Therefore, if policymakers
are inclined to devote less research funding to cancers
that arise partially as a product of poor voluntary behav-
iour, then cervical cancer and melanoma would be
expected to also be underfunded. Alternatively, if policy-
makers decide that it is not ethically tolerable to devote
reduced funding to cancers wherein victims may arise
due to their risk-inducing lifestyle choices, then lung,
liver and oral cancers should be given increased funding.
Figure 3 shows that the United Kingdom, in com-
parison to the United States, has a much higher pro-
portional YLL value for oesophageal cancer (almost
twice the relative YLL) with less dramatic elevations
apparent for stomach, bladder and prostate cancers
while exhibiting slightly lower relative burdens arising
from leukaemia, liver, oral, and uterine cancers. The
United Kingdom drinks almost four times as much
black tea as the United States on a per kg per person
ratio [25] and recent studies found that the excessive
consumption of hot tea increased the burden arising
from several gastrointestinal cancers (e.g. oesophageal,
prostate, and bladder cancer) [26–28]. Although this
pattern is far from conclusive, the presence of ele-
vated relative YLL for these cancers of the digestive
system in the United Kingdom relative to the United
States does suggest that some aspects of diet and cul-
ture may be responsible.
Figure 4 shows that although both the United Kingdom
and United States appear to greatly overfund research on
testicular cancer and leukaemia, these discrepancies are
more extreme in the United Kingdom. We do not offer an
interpretation of this difference between the countries, but
we note that the culture of science itself may foster dis-
crepancies in funding in cases such as these. New research
scientists are trained in research labs that have received
training and will naturally continue their careers in the
same sub-disciplines. The competitive nature of gaining
research funding (which often requires evidence of previ-
ous success) can create feedback loops in which areas of
research with demonstrated success result in more indi-
viduals trained in that field than in other fields. The pool
of researching scientists then resembles the types of re-
search that has been successful rather than those that may
provide the biggest societal benefit. Perhaps successful dis-
covery of treatments for testicular cancer (it has a better
than 95% cure rate) and leukaemia have perpetuated re-
search in these areas to such a degree that it now outpaces
that justified from the current societal burden. To reduce
these discrepancies arising from research focus inertia, we
recommend that researchers and funding agencies be
mindful of the potential benefits arising from supporting
research in novel areas.
In general, we found broadly similar patterns of dis-
crepancy between societal burden (as measured by YLL)
and governmental research funding in both the United
States and the United Kingdom and evidence that these
discrepancies generally improved in the United Kingdom
from 2000 to 2010. The comparison with the United
States benefited from having a recent United States data
analysis [10] with easily comparable values, but the com-
parison with the previous United Kingdom data [3] was
less than ideal due to the lack of a consistent base year
for their research funding and mortality values.
Conclusions
Discrepancies between the amount of NCRI research
funding and United Kingdom societal burden exist for
various types of cancers; some cancers are funded at
levels far higher than their relative YLL burden suggests
(testicular, leukaemia, Hodgkin’s lymphoma, breast, cer-
vical, ovarian, prostate), while others appear underfunded
(gallbladder, nasopharyngeal, lung, intestine, stomach,
pancreatic, thyroid, oesophageal, liver, kidney, bladder, and
brain/central nervous system). These discrepancies are
similar to both those that were present a decade ago in
the United Kingdom [3] and those current in the United
States [10], indicating that these discrepancies are persist-
ent and widespread. Since increased funding has been
shown to lead to increased results [29–31], shifting re-
sources from those cancers that are overfunded to those
that are underfunded may increase the overall efficiency
of cancer research with respect to reducing societal
burden.
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